These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 19503958)
21. For the Sake of Justice: Should We Prioritize Rare Diseases? Juth N Health Care Anal; 2017 Mar; 25(1):1-20. PubMed ID: 25145639 [TBL] [Abstract][Full Text] [Related]
22. Competing for public funding of medicines to treat rare disorders in New Zealand. Crausaz S Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396 [No Abstract] [Full Text] [Related]
23. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
24. The Orphan Drug Act Revisited. Thomas S; Caplan A JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155 [No Abstract] [Full Text] [Related]
25. Ethical issues in funding orphan drug research and development. Gericke CA; Riesberg A; Busse R J Med Ethics; 2005 Mar; 31(3):164-8. PubMed ID: 15738438 [TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Rai AK Soc Philos Policy; 2002; 19(2):246-70. PubMed ID: 12678089 [No Abstract] [Full Text] [Related]
28. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
29. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Gammie T; Lu CY; Babar ZU PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948 [TBL] [Abstract][Full Text] [Related]
30. The management of rare diseases. Walshe JM Clin Med (Lond); 2005; 5(1):81-2. PubMed ID: 15745209 [No Abstract] [Full Text] [Related]
31. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
32. History of Orphan Drug Regulation-United States and Beyond. Haffner ME Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514 [TBL] [Abstract][Full Text] [Related]
33. Ethical considerations in orphan drug approval and use. Kesselheim AS Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660 [TBL] [Abstract][Full Text] [Related]
34. How should we model rare disease allocation decisions? London AJ Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383 [No Abstract] [Full Text] [Related]